Cost Effectiveness of Duloxetine for Osteoarthritis: A Quebec Societal Perspective

Wielage, Ronald C.; Patel, Ankur J.; Bansal, Megha; Lee, Shannon; Klein, Robert W.; Happich, Michael

doi:10.1002/acr.22224

Cited by 13 publications

(25 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Duloxetine (vs. comparators celecoxib, diclofenac, naproxen, hydromorphone, and oxycodone) was cost effective for 55-year old pts with OA and more so in older patients and those at greater risk for adverse effects in Canada (143). Celecoxib with a proton pump inhibitor was cost effective for OA (vs. diclofenac with a proton pump inhibitor) in an analysis within the Swedish health system using an adaptation of the NICE OA model (144).…”

Section: Resultsmentioning

confidence: 99%

Osteoarthritis year in review 2015: clinical

Sharma

2016

Osteoarthritis and Cartilage

View full text Add to dashboard Cite

The purpose of this review is to highlight clinical research in osteoarthritis. A literature search was conducted using PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) with the search terms “osteoarthritis [All Fields] AND treatment [All Fields]” and the following limits activated: humans, English language, all adult 19+ years, published between April 1, 2014 and April 1, 2015. A second literature search was then conducted with the search terms “osteoarthritis [All Fields] AND epidemiology [All Fields]”, with the same limits. Reports of surgical outcome, case series, surgical technique, tissue sample or culture studies, trial protocols, and pilot studies were excluded. Of 1523, 148 were considered relevant. Among epidemiologic and observational clinical studies, themes included physical activity, early knee OA, and confidence/instability/falls. Symptom outcomes of pharmacologic treatments were reported for methotrexate, adalimumab, anti-nerve growth factor monoclonal antibodies, strontium ranelate, bisphosphonates, glucosamine, and chondroitin sulfate, and structural outcomes of pharmacologic treatments for strontium ranelate, recombinant human fibroblast growth factor 18, and glucosamine and chondroitin sulfate. Symptom outcomes of non-pharmacologic interventions were reported for: neuromuscular exercise, quadriceps strengthening, weight reduction and maintenance, TENS, therapeutic ultrasound, stepped care strategies, cognitive behavior therapy for sleep disturbance, acupuncture, gait modification, booster physical therapy, a web-based therapeutic exercise resource center for knee OA; hip physical therapy for hip OA; and joint protection and hand exercises for hand OA. Structure outcomes of non-pharmacologic interventions were reported for patellofemoral bracing.

show abstract

Section: Resultsmentioning

confidence: 99%

Osteoarthritis year in review 2015: clinical

Sharma

2016

Osteoarthritis and Cartilage

View full text Add to dashboard Cite

show abstract

“…For LBP models, horizons were as short as one episode of pain [17] to as long as lifetime [18] [19]. Time horizon was associated with model type, with the decision trees modelling the short-term horizons [17] [15] and Markov models employed for the longer-term horizons [14] [18] [19]. In terms of cycle lengths, the three Markov models which stated their cycle length, all used a cycle length of three months [14] [18] [19].…”

Section: Time Horizon Cycle Length and Discountingmentioning

confidence: 99%

“…Time horizon was associated with model type, with the decision trees modelling the short-term horizons [17] [15] and Markov models employed for the longer-term horizons [14] [18] [19]. In terms of cycle lengths, the three Markov models which stated their cycle length, all used a cycle length of three months [14] [18] [19]. All studies over year in duration ought to discount according to national guidelines [35], and all LBP studies did so appropriately.…”

Section: Time Horizon Cycle Length and Discountingmentioning

confidence: 99%

Systematic Review of Decision Analytic Modelling in Economic Evaluations of Low Back Pain and Sciatica

Hall

Konstantinou

Lewis

et al. 2019

Appl Health Econ Health Policy

View full text Add to dashboard Cite

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document. When citing, please reference the published version. Take down policy While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

show abstract

“…With recognition of person/patient centered mechanism-based management of pain, potential use of centrally acting drugs has been expanded to other chronic pain disorders. Duloxetine, which primarily works centrally, has been shown to be effective in the treatment of osteoarthritis [123][124][125] and chronic low back pain [125][126][127][128][129][130][131][132][133] . Another centrally acting drug Pregabalin has also been demonstrated to be an effective treatment of various chronic musculoskeletal pain disorders, particularly of chronic low back pain [134][135][136][137][138][139][140][141] .…”

Section: Research Highlightmentioning

confidence: 99%

Fibromyalgia or Chronic Widespread Pain: Does It Matter?

2016

Itch Pain

View full text Add to dashboard Cite

The question whether Fibromyalgia syndrome (FMS) is a distinct clinical entity in the context of chronic widespread pain (CWP) have remained challenging after decades of research and several diagnostic criteria that have attempted to clarify FMS. A recent study has raised more challenges on the issue, proposing that diagnosis of FMS in patients representing with CWP is not informative or helpful for clinical practice and such a differentiation will provide little or no significance regarding the choice of effective and safe therapies. This proposal will be further discussed here by reviewing the recent advances in the field of pain medicine. These advances have collectively provided compelling evidence that all individuals with chronic pain, even those classically categorized as originating from peripheral/nociceptive origins have common central contributions to their pain and associated comorbidities. The recent understanding of the pain mechanisms has also provided important implications on classification and management of pain. Centrally acting agents have been recommended as first-line treatment options for FMS and potential use of these agents has been expanded to other chronic pain disorders. After having reviewed the recent advances in the pain field, distinction between CWP and FMS still seems not to be useful in clinical practice, as effective treatment in an individual patient might be much guided by dominant underlying mechanisms rather than specific diagnosis the patient is suffering. The conditions representing with CWP in the absence of definitive objective confirmation may then be classified under one heading such as "CWP", "chronic pain syndrome" or "central pain", when considering their similar pattern of clinical presentation, commonality of central sensitization to their pathophysiology and their similar response to centrally acting analgesics. Future research should be directed toward classification of CWP based on the validated measurements of different aspects of pain. Such a classification may help clinicians identify the patients who will preferentially respond to peripheral or centrally acting analgesics and may therefore assist in advancing a more individualized and pain mechanism focused treatment in the clinical setting.

show abstract

Cost Effectiveness of Duloxetine for Osteoarthritis: A Quebec Societal Perspective

Cited by 13 publications

References 25 publications

Osteoarthritis year in review 2015: clinical

Osteoarthritis year in review 2015: clinical

Systematic Review of Decision Analytic Modelling in Economic Evaluations of Low Back Pain and Sciatica

Fibromyalgia or Chronic Widespread Pain: Does It Matter?

Contact Info

Product

Resources

About